GlassScriptPhysician profile
Shawn Miller
NPI 1124106745
$2,504.15
in general payments reported to CMS, 2019-2025
20 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $257 · 2021: $349 · 2022: $431 · 2023: $252 · 2024: $128 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $506.83 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $349.59 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbott Laboratories | $293.21 | 2021-2022 | |
| Amarin Pharma, INC. | $288.48 | 2019-2022 | |
| Pfizer INC. | $174.82 | 2019-2023 | |
| Glaxosmithkline, LLC. | $158.82 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Boston Scientific Corporation | $147.30 | 2021-2025 | Intracept |
| Lilly USA, LLC | $130.65 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $109.52 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $98.64 | 2019-2022 | |
| Sanofi Pasteur INC. | $51.62 | 2019 | |
| Alnylam Pharmaceuticals INC. | $29.57 | 2023 | Onpattro |
| Edwards Lifesciences Corporation | $27.47 | 2025 | |
| Exact Sciences Corporation | $25.67 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.96 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $19.88 | 2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $19.28 | 2023 | Xarelto |
| Merck Sharp & Dohme LLC | $19.26 | 2025 | Gardasil 9, Capvaxive |
| Idorsia Pharmaceuticals US INC | $17.62 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $14.96 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.